Palsy

Summary

Palsy (MONDO:0006496) is a disease (an umbrella term covering 10 Mondo subtypes) and 5 clinical trials. A subtype of central nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 10 Mondo subtypes
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	palsy
Mondo ID	MONDO:0006496
EFO	EFO:1000631
MeSH	D010243
ICD-10-CM	G80-G83
UMLS	C3887651
MedGen	854494
Is cancer (heuristic)	no

Also known as: Plegia · Plegias

Disease family

This is a subtype of central nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › palsy

Related subtypes (18): autoimmune disorder of central nervous system, autonomic nervous system disorder, optic nerve disorder, spinal cord disorder, high pressure neurological syndrome, central nervous system vasculitis, encephalomyelitis, neurodegenerative disease, brain disorder, central nervous system neoplasm, trigeminal neuralgia, infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly, sporadic fetal brain disruption sequence, congenital narrowing of cervical spinal canal, central nervous system infectious disorder, cerebrospinal fluid leak, SPAST-related motor disorder, tinnitus

Subtypes (10): hemiplegia, quadriplegia, facial paralysis, ophthalmoplegia, paraplegia, cerebral palsy, progressive bulbar palsy, klumpke’s paralysis, respiratory paralysis, Erb palsy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ropivacaine	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01579604	PHASE4	UNKNOWN	Nerve Transfer Reconstruction in the Tetraplegic Upper Extremity
NCT01169181	PHASE1	UNKNOWN	AMES + Brain Stimulation
NCT00212394	Not specified	COMPLETED	Tourniquet Complications in Orthopaedic Surgery
NCT00833105	Not specified	COMPLETED	Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury
NCT01116544	Not specified	COMPLETED	Treatment of Chronic Stroke With AMES + EMG Biofeedback